Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?

Angelica Tiotiu (1, 2) , Claire Poreaux (1) , Pascal Poncet (3, 4) , Hélène Senechal (4) , J.L. Schmutz (1, 5)

1 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
2 DevAH - Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité
3 Centre d'Innovation et Recherche Technologique / Center for Innovation and Technological Research
4 CHU Trousseau [APHP]
5 Faculté de Médecine [Nancy]

Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Biochemistry, Molecular Biology; Biochemistry [q-bio.BM]; Life Sciences [q-bio]; Ecology, environment; Health; Life Sciences [q-bio]; Immunology; Allergology

Angelica Tiotiu, Claire Poreaux, Pascal Poncet, Hélène Senechal, J.L. Schmutz. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?. European Journal of Dermatology, 2019, 29 (1), pp.101-2. ⟨10.1684/ejd.2018.3454⟩. ⟨pasteur-03718435⟩